Navigation Links
Rigel Announces Presentations at Two Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, executive vice president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows:

    Oppenheimer 20th Annual Healthcare Conference
    Waldorf Astoria, New York City, NY
    November 3, 2:10 p.m. EST
    Speaker: Raul R. Rodriguez

    Credit Suisse 18th Annual Healthcare Conference
    Arizona Biltmore Hotel, Phoenix, AZ
    November 11, 2:00 p.m. MST
    Speaker: James M. Gower

Both presentations will be webcast. To access the live webcast or the subsequent archived recording, log on to Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

    Contact: Raul R. Rodriguez
    Phone: 650-624-1302

    Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
    Phone: 650.430.3777

SOURCE Rigel Pharmaceuticals, Inc.

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
2. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
5. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
6. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
9. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
10. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
11. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):